Neuromyelitis Optica Spectrum Disorder  >>  Phase 1
Welcome,         Profile    Billing    Logout  

4 Trials

   Remove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Neuromyelitis Optica Spectrum Disorder
NCT05432713: A Study of LP-168 in Healthy Volunteers

Completed
1
70
RoW
LP-168 tablet, NWP-775, LP-168 Placebo tablet, NWP-775 Placebo
Guangzhou Lupeng Pharmaceutical Company LTD.
Multiple Sclerosis, NMO Spectrum Disorder
11/22
12/22
NCT04146285: A Phase I Clinical Trial of BAT4406F Injection in Patients With Neuromyelitis Optica Spectrum Disorders

Recruiting
1
15
RoW
BAT4406F
Bio-Thera Solutions
Neuromyelitis Optica Spectrum Disorders
03/23
06/23
NCT05145361: Clinical Study of B001 Injection in Subjects With Neuromyelitis Optic Spectrum Disorder (NMOSD)

Recruiting
1
45
RoW
B001 injection, Placebo
Shanghai Pharmaceuticals Holding Co., Ltd
NMO Spectrum Disorder
12/24
12/24
CARTinNS, NCT04561557: Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous System

Recruiting
1
36
RoW
CT103A cells, Cyclophosphamide and fludarabine
Tongji Hospital, Nanjing IASO Biotechnology Co., Ltd.
Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Neuromyelitis Optica Spectrum Disorder, Myasthenia Gravis, Chronic Inflammatory Demyelinating Polyradiculoneuropathy, Idiopathic Inflammatory Myopathies, Multiple Sclerosis, Autoimmune Encephalitis, Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD), POEMS Syndrome
02/27
05/27

Download Options